Unknown

Dataset Information

FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial.


ABSTRACT:

Background

Acne vulgaris has increased in women over the past 10 years; it currently affects 20-30% of women. The physiopathology of adult female acne is distinguished from that of teenagers essentially by two factors: hormonal and inflammatory. On a therapeutic plan, the four types of systemic treatment approved for female acne include cyclines (leading to bacterial resistance); zinc salts (less effective than cyclines); and antiandrogens (risks of phlebitis). The last alternative is represented by isotretinoin, but its use in women of childbearing potential is discouraged because of the teratogen risks. In this context, spironolactone could represent an interesting alternative. It blocks the 5-alpha-reductase receptors at the sebaceous gland and inhibits luteinizing hormone (LH)

SUBMITTER: Poinas A 

PROVIDER: S-EPMC7318446 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature